This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through June 1, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
EVMN Stock Tanks as Phase IIb Urticaria Study Misses Primary Goal
by Zacks Equity Research
Evommune shares fall after its phase IIb CSU study misses the primary endpoint, prompting the company to halt further development of EVO756 for the indication.
EVMNNegative Net Change LQDANegative Net Change KNSANegative Net Change IMCRNegative Net Change
biotechs
CRMD's Growth Story Expands Beyond DefenCath Into New Trends
by Ahan Chakraborty
CorMedix broadens beyond DefenCath with Melinta assets, Rezzayo potential and cost synergies as reimbursement changes test long-term earnings durability.
CRMDPositive Net Change PFENegative Net Change BAXPositive Net Change
biotechnology biotechs medical pharmaceuticals
CRMD Stock Outlook as DefenCath and Rezzayo Expand Growth Path
by Ahan Chakraborty
CorMedix is shifting from a single-product launch story as DefenCath drives revenue and Rezzayo adds long-term potential despite reimbursement headwinds.
CRMDPositive Net Change PFENegative Net Change AMPHNegative Net Change
biotechnology biotechs medical pharmaceuticals
Is CRMD Stock a Buy Now After Strong Growth and New Risks?
by Ahan Chakraborty
CorMedix posted surging DefenCath-led revenue and stronger profitability, but reimbursement changes and execution risks could shape the stock's next phase.
CRMDPositive Net Change PFENegative Net Change AMPHNegative Net Change
biotechnology biotechs medical pharmaceuticals
Can Eli Lilly's New Drugs Fuel Growth Beyond Its GLP-1 Blockbusters?
by Ahan Chakraborty
LLY is expanding its revenue base beyond Mounjaro and Zepbound with new launches and label expansions that can strengthen long-term growth.
LLYNegative Net Change NVOPositive Net Change VKTXNegative Net Change GPCRNegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Theravance Stock Down 3% After Zymeworks Announces Buyout
by Zacks Equity Research
TBPH falls after agreeing to a $929 million all-cash acquisition by Zymeworks, following a strategic review triggered by its failed ampreloxetine program.
TBPHNegative Net Change ZYMENegative Net Change VTRSPositive Net Change
biotechs
5 Low P/B Stocks That Investors Can Add to Their Portfolio in July
by Kinjel Shah
PAGS, USNA, GM, NEXA and AVT stand out after passing low price-to-book value screens, highlighting five stocks that merit a closer look in July.
AVTNegative Net Change GMNegative Net Change USNAPositive Net Change NEXANegative Net Change PAGSNo Net Change
auto-tires-trucks biotechs medical precious-metals
Biotech ETF (BBC) Touches a New 52-Week High
by Sanghamitra Saha
The BBC ETF hit a 52-week high as strong trial updates and biotech momentum raise hopes for more gains ahead.
BBCNegative Net Change
biotechs etfs
INCY Stock Hits 52-Week High on Regulatory Updates for Opzelura
by Zacks Equity Research
Incyte shares hit a 52-week high as Opzelura gains regulatory momentum, pipeline advances and a CMS settlement boosts investor sentiment.
INCYPositive Net Change NVSNegative Net Change MIRMPositive Net Change
biotechnology biotechs medical pharmaceuticals
HRMY Growth Trends Beyond Wakix Could Shape Its Next Growth Phase
by Ekta Bagri
Harmony Biosciences is broadening beyond Wakix with pitolisant programs, orexin research and rare epilepsy assets to diversify growth.
HRMYNegative Net Change ALKSNegative Net Change JAZZNegative Net Change
biotechnology biotechs